Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Coagulation Factor VII Human

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 3Haemophilia

    02 3Haemophilia A

    03 2NovoSeven

    04 1of which Novoseven

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Haemophilia

    Recombinant Human Coagulation Factor VIIa

    arrow
    BPI Europe
    Not Confirmed

    Brand Name : Haemophilia

    Denmark
    arrow
    BPI Europe
    Not Confirmed

    Novo Nordisk

    Recombinant Human Coagulation Factor VIIa

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 1,571

    2019 Revenue in Millions : 1,672

    Growth (%) : -6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Haemophilia A

    Recombinant Human Coagulation Factor VIIa

    arrow
    PCC
    Not Confirmed

    Brand Name : Haemophilia A

    Denmark
    arrow
    PCC
    Not Confirmed

    Novo Nordisk

    Recombinant Human Coagulation Factor VIIa

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 322

    2020 Revenue in Millions : 274

    Growth (%) : 23

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Haemophilia A

    Recombinant Human Coagulation Factor VIIa

    arrow
    PCC
    Not Confirmed

    Brand Name : Haemophilia A

    Denmark
    arrow
    PCC
    Not Confirmed

    Novo Nordisk

    Recombinant Human Coagulation Factor VIIa

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 341

    2021 Revenue in Millions : 322

    Growth (%) : 6

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : NovoSeven

    Recombinant Coagulation Factor VIIa

    arrow
    PCC
    Not Confirmed

    Brand Name : NovoSeven

    Denmark
    arrow
    PCC
    Not Confirmed

    Novo Nordisk

    Recombinant Coagulation Factor VIIa

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2023 Revenue in Millions : 1,157

    2022 Revenue in Millions : 1,212

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Haemophilia A

    Recombinant Human Coagulation Factor VIIa

    arrow
    PCC
    Not Confirmed

    Brand Name : Haemophilia A

    Denmark
    arrow
    PCC
    Not Confirmed

    Novo Nordisk

    Recombinant Human Coagulation Factor VIIa

    Main Therapeutic Indication : Rare Diseases

    Currency : USD

    2023 Revenue in Millions : 352

    2022 Revenue in Millions : 341

    Growth (%) : 4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : NovoSeven

    Recombinant Coagulation Factor VIIa

    arrow
    PCC
    Not Confirmed

    Brand Name : NovoSeven

    Denmark
    arrow
    PCC
    Not Confirmed

    Novo Nordisk

    Recombinant Coagulation Factor VIIa

    Main Therapeutic Indication : Rare Diseases and Disorders

    Currency : USD

    2024 Revenue in Millions : 1,107

    2023 Revenue in Millions : 1,157

    Growth (%) : -4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Haemophilia

    Recombinant Human Coagulation Factor VIIa

    arrow
    PCC
    Not Confirmed

    Brand Name : Haemophilia

    Denmark
    arrow
    PCC
    Not Confirmed

    Novo Nordisk

    Recombinant Human Coagulation Factor VIIa

    Main Therapeutic Indication : Blood Disorders

    Currency : USD

    2018 Revenue in Millions : 1,436

    2017 Revenue in Millions : 1,570

    Growth (%) : -9%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : of which Novoseven

    Coagulation Factor VII [Recombinant]

    arrow
    PCC
    Not Confirmed

    Brand Name : of which Novoseven

    Denmark
    arrow
    PCC
    Not Confirmed

    Novo Nordisk

    Coagulation Factor VII [Recombinant]

    Main Therapeutic Indication : Blood Disorders

    Currency : USD

    2018 Revenue in Millions : 1,182

    2017 Revenue in Millions : 1,381

    Growth (%) : -14%

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Haemophilia

    Recombinant Human Coagulation Factor VIIa

    arrow
    Bioprocess International Europe
    Not Confirmed

    Brand Name : Haemophilia

    Denmark
    arrow
    Bioprocess International Europe
    Not Confirmed

    Novo Nordisk

    Recombinant Human Coagulation Factor VIIa

    Main Therapeutic Indication : Hematology

    Currency : USD

    2019 Revenue in Millions : 1,542

    2018 Revenue in Millions : 1,436

    Growth (%) : 7

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.